MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-09-2023
Applied Molecular Transport Total Non Current Liabilities 2011-2026 | AMTI
Annual Total Non Current Liabilities Applied Molecular Transport
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 106 M | 64.2 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 106 M | 64.2 M | 85.2 M |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aligos Therapeutics
ALGS
|
15 M | $ 8.64 | 8.07 % | $ 85.4 M |  USA |
 |
Allakos
ALLK
|
8.11 M | - | - | $ 28.6 M | USA |
 |
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
10.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
73.6 K | $ 3.66 | -1.48 % | $ 8.81 B |  Australia |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
332 | $ 3.11 | 5.42 % | $ 265 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | France |
 |
Brainstorm Cell Therapeutics
BCLI
|
618 K | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
797 K | - | - | $ 8.42 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
BeiGene, Ltd.
BGNE
|
2 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
219 M | - | - | $ 546 M | USA |
 |
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Cabaletta Bio
CABA
|
43.9 M | $ 3.2 | 2.24 % | $ 322 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
69.4 M | $ 21.36 | 4.86 % | $ 998 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
2.47 M | - | - | $ 169 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | USA |
 |
Clearside Biomedical
CLSD
|
4.72 M | - | - | $ 25.3 M | USA |
 |
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
168 M | $ 1.47 | 5.0 % | $ 378 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.19 M | $ 2.92 | - | $ 4.81 M |  Israel |
 |
Aquestive Therapeutics
AQST
|
90.3 M | $ 4.19 | 2.7 % | $ 448 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
167 M | $ 24.12 | -0.37 % | $ 3.07 B | USA |
 |
Chimerix
CMRX
|
196 K | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
17.9 M | - | - | $ 401 M | USA |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
17.3 M | $ 32.59 | 1.09 % | $ 2.16 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.47 | -1.34 % | $ 391 M | Britain |
 |
Aptose Biosciences
APTO
|
27.9 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Cidara Therapeutics
CDTX
|
942 K | - | - | $ 1.41 B | USA |
 |
AVROBIO
AVRO
|
276 K | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
30.8 B | - | - | $ 96.9 B | Britain |
 |
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | USA |
 |
CTI BioPharma Corp.
CTIC
|
1.17 M | - | - | $ 1.2 B | USA |
 |
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | Germany |
 |
Akari Therapeutics, Plc
AKTX
|
50 K | $ 4.25 | 8.35 % | $ 286 B | Britain |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |